If Dharmanol beta testers describe themselves as "feeling

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles
If Dharmanol beta testers describe themselves as "feeling surprisingly well and healthy" along with feelings of relaxed well-being; banished anxiety; no drowsiness; enhanced activity function; normal pulse, hearing and vision; mental acuity; no psycho-actvity; and quelling of urge to smoke cannabis, how much is the brand worth? This might give some idea. It's a bit dated but tells the story well enough.

Tranquillizers — Sleeping Pills — Anti-Depressants
1

Worldwide sales of prescription drugs exceed $300 billion yearly with tranquillizers, sleeping pills, anti-depressants and other Central Nervous System drugs accounting for an estimated $76 billion in sales.

2

Inappropriate prescribing and uninformed use of prescriptions cost healthcare systems billions of dollars worldwide yearly.

3

Prescription Drugs are the fastest growing sector of worldwide health care costs with health care costs continuing to be the largest component of most governments budgets.

4

Prescription Drugs are fast exceeding the cost of physician services.

5

Benzodiazepines have often been called the most widely prescribed group of drugs in the world and the biggest selling drugs in the history of medicine with worldwide sales in excess of $21 billion in 1999.

6

Approximately 10% – 20% of the world population use tranquilizers and sleeping pills with up to 30% of people over the age of 60 years using these drugs (often over many years having been prescribed them at a much earlier age) and who have become "accidental or involuntary addicts."

7

By law, when a physician prescribes drugs for a patient, the physician is required to ensure that the patient is fully informed of the drugs risks and benefits and consents to the drug therapy with full informed knowledge. Statistics show that this occurs in less than 20% of the patient population.

8

An estimated 4 million people in the United States have used prescribed benzodiazepine tranquillizers and hypnotics (sleeping pills) regularly for 5 – 10 years or more according to a US study in the early 1990s. Similar figures apply in the UK, Europe and in some Asian countries with the trend continuing.

9

The World Health Organization (WHO) estimates that 33% of diseases today are caused by medical treatment i.e. iatrogenic or doctor induced illness. Doctors are the third leading cause of death in the US after heart disease and cancer causing an estimated 250,000 deaths each year according to an article published in the Journal of the American Medical Association, July 2000.

10

An estimated 60% of users of tranquilizers and sleeping pills suffer a mixture of adverse effects and withdrawal after 2 – 4 weeks of use (including therapeutic dose levels) due to tolerance and addiction.

11

Addiction to prescription drugs such as tranquillizers and sleeping pills is the inability to discontinue the use of the drugs as a direct result of the build up of tolerance and when the original dose has progressively less effect and a higher dose is required over time. Tolerance produces a recognized withdrawal syndrome and can precipitate "mini withdrawals" "or inter dose withdrawals" between pills depending on the "half life" of the drugs. This often leads to doctors prescribing increased dosages and/or prescribing another benzodiazepine and/or cross addictions to other drugs, primarily alcohol, to withstand the withdrawal symptoms.

12

Pharmaceutical companies spend more on marketing and promotion of drugs than on research and development — an estimated $15,000 – $20,000 on every doctor with expenditures of $8.3 billion in the United States in 1998.

13

40% of impaired or dead drivers of motor vehicles show prescription drugs in their systems – predominantly tranquillizers and sleeping pills.

14

The adverse effects of benzodiazepines can include: paradoxical agitation, increased behavioural disinhibition, impaired new learning, decreased short and long-term memory, impaired psycho-motor functioning, (many times leading to accidents and/or falls), rage, the appearance or worsening of anxiety and depression, suicidal ideation, emotional anesthesia, floppy baby syndrome, the potential for permanent cognitive impairment, tolerance and addiction leading to acute and protracted withdrawal. These effects have been known for over 2 decades but little has been done to address the problem or to change doctors prescribing habits.

15

The National Centre on Addiction and Substance Abuse at Columbia University in 2001 found that General Practitioners don't properly assess for addictions and alarmingly, fewer than one third can diagnose addiction to prescription drugs — a problem doctors create.

16

Guidelines for acceptable duration of benzodiazepine use dating back over 2 decades state a maximum of 2 – 4 weeks or for intermittent use only. Most recently, guidelines state 7 – 10 days.

17

The infrastructure — detox, treatment and recovery centres available and doctors knowledgeable to help people withdraw from tranquillizers, sleeping pills and anti-depressants — is minimal, and in many cases non existent.

18

Misdiagnosis, misprescribing and mistreatment of patients who trust their doctors to "do no harm" continue today in the area of tranquilizers, sleeping pills and anti-depressants.

19

The high cost to our socio-economic system with the continued indiscriminate prescribing and uninformed usage of these drugs includes health and safety in the work place, career devastation, family dysfunction, productivity losses, car accidents, falls, floppy baby syndrome (similar to fetal alcohol syndrome), lost years of people's lives, lost lives, costs to the legal and justice system, workers' compensation board claims, life and disability insurance claims, social welfare costs, emergency admissions, physicians' fees, pharmacists' fees, drug costs, detox facilities and increased overall costs for healthcare and other public/private sector services.

20

The elderly receive more than twice the number of prescription for psychotropic drugs as do younger people and can experience drug induced dementia, cognitive impairment and falls after years of use.

21

Non "psychiatric" conditions account for 70% of tranquillizer and sleeping pill prescribing and usage.

22

Cross addictions to other drugs and alcohol occur in 73% of benzodiazepine users — many of whom never used or had problems with alcohol or other drugs previously.

23

43% of emergency room suicide attempts or overdoses involve tranquillizers and sleeping pills.

24

Prescription drug addiction to benzodiazepines is far more gripping and debilitating than addiction to heroin or cocaine. Withdrawal is recognized to be more difficult, more prolonged and can last months or years depending on the years of use, dosage and the concurrent prescribing with other drugs.

25

Withdrawal symptoms from tranquillizers and sleeping pills can include insomnia, panic attacks, agitation, hallucinations, paranoia, depersonalization, derealization, depression, pressure in head, anxiety, loss of appetite, weight loss, visual distortions, flashbacks, lack of concentration, agoraphobia, dizziness, sweating, nausea, nightmares, palpitations, creeping sensation in the skin, increased sensitivity to light, touch and smell, pins and needles, numbness, seizures and sometimes death. A too rapid withdrawal causes major hyper excitability of the brain and central nervous system. A slow taper of weeks and months depending on use is recommended under close, ongoing medical supervision by a knowledgeable doctor and/or addiction specialist.

26

A Canadian report released in May 1999 revealed that in 1997 benzodiazepine prescriptions surpassed all other Phamacare prescriptions for women exceeding cardiac drugs, anti-depressants and estrogen. 67% of prescriptions were issued to women.

27

68% of people prescribed tranquillizers and sleeping pills receive their prescriptions from only one doctor.

28

A 1996 study at Stockholm University in Sweden revealed that 51% of patients dependent on sedative/hypnotic drugs (tranquillizers and sleeping pills) showed signs of acquired intellectual deterioration and impairment (which can be permanent).

29

Substance use and mental illness co exist in an estimated 50% – 70% of patients diagnosed with "alleged psychiatric disorders". The DSM III and DSM IV (psychiatric manuals) document substance induced anxiety disorders, substance induced mood disorders and substance induced depressive disorders caused by benzodiazepine use. These "alleged psychiatric disorders" often disappear once a patient is off all medications and as a result of lifestyle changes including exercise and diet.

30

There is extensive worldwide concurrent prescribing of benzodiazepines with antidepressants to approximately 60% of patients/consumers (often prescribed to counteract the adverse/side effects of one category of drugs with another).

31

Many patients are prescribed several different benzodiazepines and several different anti-depressants at the same time. In some cases, patients are further prescribed neuroleptics and then anti psychotics. It is not unsual to find patients on 3 – 7 different nervous system drugs. This is all part of a market "dollar-driven" healthcare system based on an antiquated "disease model" and dependent on a chemical cocktail of drugs.

32

A booming market also exists for anti-depressants such as Prozac, Paxil, Zoloft, Luvox, Wellbutrin and Effexor with worldwide sales in the billions of dollars. Anti-depressants (often referred to as the follow up to Valium 25 years later) in the United States in 2000 reached $10.4 billion in retail sales up 21% over 1999 and representing a startling five-fold increase since 1993.

33

In the United States in 2000 Prozac sales (Eli Lilly) reached $2.6 billion, Zoloft (Pfizer) reached $1.9 billion, Paxil (Smith Kline Beecham) $1.8 billion, Wellbutrin (Glaxo Smith Kline) $850.9 million and Effexor (Wyeth - Ayerst) $815.8 million.

34

Anti-depressants including Prozac, Paxil, Zoloft, Luvox and Celexa can have significant side effects including drug induced mania leading to suicide, suicidal ideation, violence, criminal acts, disinhibition or out of control behaviour; drug induced severe anxiety, agitation and depressions; drug induced obsessions and compulsions; drug induced akathisia (an internal sensation of agitation or discomfort that drives a person to move about and also to lose impulse control); tolerance and addiction leading to a recognized withdrawal syndrome which can include bouts of overwhelming depression, insomnia, fatigue and life-threatening physical effects, psychosis and violent out bursts.

35

During the past decade and with greater frequency, there has been an alarming increase in murder/suicides, suicides, domestic violence, bizarre mass killings, mother (parents) killing children, road and air rage, school shootings and workplace violence in North America where documented evidence has shown the involvement of Prozac, Paxil, Zoloft, Luvox, SSRI/Anti-depressant drugs and/or other mind altering drugs.

36

Most monographs and drug formularies for anti-depressant drugs state "effectiveness and safety in long term use has not been evaluated". Concern has also been expressed regarding anti-depressant prescribing to young children and adolescents (since these drugs have not been approved for use in children under 18 years of age). One million children in the US were reported taking anti-depressants in 1999 — including mint flavoured Prozac.

37

Safe use of anti-depressants during pregnancy has not been established with drug monographs and drug formularies stating that anti-depressants should not be administered to women of child bearing potential unless in the opinion of the treating physician the expected benefits to the patient markedly out weigh the possible hazards to the child or fetus.

38

Prescription Drugs are big business with high profits. The ongoing creation by major international drug companies of expanded markets and new markets for antidepressants include new "alleged diseases" such as "social anxiety disorder" for which Paxil is being promoted heavily in advertising; Prozac as Serafem to treat "mood imbalances associated with premenstrual syndrome" and since Prozac has gone off patent, the drug manufacturer, Eli Lilly has received approval to market a once-weekly version of the drug (based on its "new coating").

39

The drugging of children with Ritalin, another highly addictive central nervous system stimulant, continues with increasing regularity and controversy with Ritalin use nearing a world record. In the United States, usage of Ritalin increased an estimated 70% between 1990 and 1998. Is it a question of "hook" them young and they are customers for life to addictive prescription drugs including tranquillizers, sleeping pills and anti-depressants?

Sources: International research and statistics compiled over 12 years from various sources


Market Media International Corp.
4507 Cedarcrest Avenue,
North Vancouver, BC
V7R 3R2,
Canada


SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Updated Category News Views 224

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Continue Reading
Knob-and-Tube Wiring: A Hidden Hazard Unveiled

Updated Category News Views 99

Unlocking the Mysteries of Knob-and-Tube Wiring Ever wondered if the wiring in your charming hundred-year-old home might be a ticking time bomb? Welcome to the world of knob-and-tube wiring. This blast from the past might just be hiding in those walls and could spell trouble. The History and Hazards of Knob-and-Tube This wiring system dates back to the 1880s, sticking...

Continue Reading
Lily Toxicity in Cats: Urgent Action Matters

Updated Category News Views 255

Understanding the Severity of Lily Toxicity Ah, lilies. They might look pretty on your dining table, but if you’ve got a feline prowling around your house, these beauties could be a silent cat killer. In the animal-medicine world, this isn’t just another cautionary tale; it's a full-blown call to arms for cat owners. Dr. Ashley Wheatley, a veterinary expert out of...

Continue Reading
OlloBot's Emotional AI Robots Connect Beyond Tasks

Updated Category News Views 394

OlloBot Eyes Emotional Bonds, Not Just Robotics Power Is it just me, or is OlloBot onto something deep with their emotional AI companions? They've set a course that might just redefine how we perceive home robotics. At IFA Berlin 2026, they didn't just strut their technical stuff. Nope, they took it beyond gears and gadgets, turning heads with a robot that does more than...

Continue Reading
Perion Acquisition: Affle's Bold Leap in Ad Tech

Updated Category News Views 119

Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...

Continue Reading
Double Down for Veterans Raises $20 Million Goal

Updated Category News Views 152

Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...

Continue Reading
Millions Tune In to 'Dedicate' Premiere in Manila

Updated Category News Views 0

Gathering for a New Kind of Celebration With a buzz louder than a crowded trading floor on a bull day, folks are flocking to catch the ripple effect of "Dedicate." Over 2 million views already, and it hasn't even hit the major radar yet—that's some serious fire in the storytelling world. The premiere in Manila, held at the Missionary Training Center (MTC), was no small...

Continue Reading
Decoding LRV: Smart Paint Choices for Your Home

Updated Category News Views 194

Unraveling the Secrets of LRV Nobody thought analyzing paint meant diving into light reflectance values (LRV), but that's precisely where we're headed today. Painting a room seems simple until you realize your color choice might turn your bright haven into a cave or vice versa. Thanks to some insights from Wendy Anguiano in HelloNation, let's dig into this technical...

Continue Reading
Nicely Network: Top Reddit Marketing for Big Brands

Updated Category News Views 166

Reddit and AI: Nicely Network's Winning Formula Straight out of New York comes the latest scoop: Nicely Network's been crowned king of the Reddit jungle, earning the title of Best Reddit Marketing Agency for Enterprise Brands this November, courtesy of Better Business Advice. Now, if you've been paying any attention to how brands are grappling with the impossible search...

Continue Reading
AI-Powered Bank Set to Transform Bahrain's Financial Landscape

Updated Category News Views 127

A Fresh Approach to Banking in Bahrain The stuff that's stirring the pot in Bahrain’s financial sector right now? This big ol' partnership between Mumtalakat, the Kingdom's sovereign wealth fund, and ARP Group. They're on a mission to launch an AI-native wholesale bank smack dab in Bahrain. But here’s the kicker – they’ve got the green light, in principle at...

Continue Reading
ection>

Top 5 Most Recently Viewed Articles

Advancements in Neurodegenerative Research by Annovis Bio

Updated Category News Views 270

Advancements Unveiled by Annovis Bio Today, Annovis Bio Inc. (NYSE: ANVS) shares exciting milestones achieved in the field of neurodegenerative disease treatment. The company, known for pioneering innovative therapies specifically targeting conditions such as Alzheimer’s disease and Parkinson’s disease, has recently provided updates on its corporate progress alongside...

Continue Reading
incident.io Secures $62M in Funding to Enhance AI Incident Response

Updated Category News Views 724

incident.io Secures $62 Million to Innovate AI-Powered Incident Management incident.io, an end-to-end incident management platform, has successfully raised $62 million in Series B funding to enhance its capabilities in AI-driven incident resolution. This significant funding round was led by Insight Partners, with continued support from Index Ventures and Point Nine...

Continue Reading
Mynd.ai, Inc. Reports 2024 Financial Results and Insights

Updated Category News Views 303

Mynd.ai, Inc. Financial Overview for 2024 The financial results for Mynd.ai, Inc. (NYSE American: MYND) reveal several key highlights from the recently concluded fiscal year. In a significant strategic shift, the company successfully conducted the sale of a non-strategic business unit, optimally reducing its operational debts while proactively initiating a share...

Continue Reading
ADT Inc. Plans to Unveil Third Quarter Financial Results

Updated Category News Views 147

ADT Inc. Financial Results Release ADT Inc. (NYSE: ADT) is gearing up to unveil its financial results for the third quarter of 2025 before the markets open on a Tuesday in early November. This anticipated event will be pivotal for stakeholders as it provides crucial insights into the company's performance. Conference Call Details Following the release of the financial...

Continue Reading
ivision Earns Microsoft Solutions Partner Status in Applications

Updated Category News Views 94

ivision Earns Microsoft Solutions Partner Designation ivision is thrilled to announce its achievement of the Microsoft Solutions Partner designation for Business Applications. This accolade highlights the firm’s extensive expertise in enhancing client operations through Dynamics 365 and the Microsoft Power Platform. A Commitment to Excellence This designation...

Continue Reading